Will it work?
It was the question everyone around Susannah Rosen kept asking. Since infancy, she’d lived with a rare neurologic disease. She’d struggled to walk and talk, only to have the degenerative disease mostly rob her of those skills. Hardly a day passed without her suffering seizures, leaving her in need of constant care.
But in October 2022, Susannah’s family had reason to be hopeful. Scientists had developed a bespoke treatment for her, a snippet of genetic code targeting the gene at the heart of those symptoms. And a doctor had just injected this therapy into the 8-year-old’s spine. From there it would wend its way to her brain.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
